€57,48 €47,50 excl. VAT
Gangliosidosis (GM2, O-variant, type 2) is a fatal, progressive neurodegenerative lysosomal storage disease caused by a deficiency of β-hexosaminidase.
10 working days
€5,95 shipping and administration per order (incl. VAT)
Specifications
Breeds | |
---|---|
Gene | |
Organ | |
specimen | Swab, Blood EDTA, Blood Heparin, Semen, Tissue |
Mode of Inheritance | |
Chromosome | |
Also known as | |
Year Published |
General information
Gangliosidosis (GM2, O-variant, type 2) is a fatal, progressive neurodegenerative lysosomal storage disease caused by a deficiency of β-hexosaminidase. The enzyme is composed of a dimer of two subunits α and β encoded by genes HEXA and HEXB. GM2 gangliosidosis can be caused by defects in the genes HEXA (Tays–Sachs disease, B-variant; where only the isoform A is deficient), HEXB (Sandhoff disease, O-variant; where both isoforms are involved). Mutations within the variants of β-hexosaminidase allow a build-up of toxic substances in the nerve cells (mainly neurons). An autosomal recessive mutation in HEXB is observed in the poodle. A related mutation of this gene is found in the Shiba Inu.
Clinical features
Dogs affected with Gangliosidosis can show a variety of symptoms including lack of coordination, depression, behavioral changes, head shaking, mental dullness, seizures, blindness, deafness, developmental delay. Specific to GM2-0: tremors, vision loss, vomiting and balance loss ( 9-12 months of age) - death at 18-23 months of age.
Additional information
References
Pubmed ID: 22766310
Omia ID: 1462